4 Stay-At-Home Funds To Continue Gaining Amid JNJ Vaccine Halt

Image: Bigstock

The U.S. economy’s progress depends highly on progress in the vaccination front. Pfizer-BioNTech and Moderna’s two-shot vaccine still holds the majority of the 192 million shots that have been so far administered to Americans, 7.5 million have received Johnson & Johnson’s one-shot vaccine. However, as of Apr 12, six women out of 1.5 million vaccinated with JNJ’s shots between the ages of 18 and 48 have rare and severe type of blood clots and have developed symptoms, most often headaches, six to 13 days after vaccination.

Hence, Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) rerecommended an immediate halt on the JNJ vaccine. Notably, JNJ’s vaccine played a significant role in the vaccination progress in America as this single-shot vaccine could remain on the shelf for at least a week and is 66% effective in preventing cases of moderate-to-severe illness and 85% effective against severe cases of COVID-19. A federal vaccine advisory committee that is currently overseeing the investigation wanted more data before deciding whether to resume use and CDC agreed to reassemble within 10 days as the vaccine plays a prime role in the battle against the pandemic.

While the government and pharmaceuticals continue to do their part in making rapid progress in vaccination, the virus has continued mutation and has emerged in several variants across the globe. These fast-spreading coronavirus variants create a challenge for business, schools and the economy as a whole. Investors who were earlier moving out of technology stocks or funds and investing in cyclicals are now moving back to stay-at-home players given the vaccine setbacks dampening economic growth.

4 Fund Picks

Given the current scenario, we have shortlisted four mutual funds that have significant exposure to companies benefiting from the stay-at-home practices and carry a Zacks Mutual Fund Rank #1 (Strong Buy). Moreover, these funds have encouraging year-to-date (YTD) returns. Additionally, the minimum initial investment is within $5000. We expect these funds to outperform their peers in the future.

1 2 3
View single page >> |

Disclaimer: Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.